Recce Pharmaceuticals Ltd. · ASX:RCE

Recce Pharmaceuticals — Shareholder Meeting (November 2016)

18 slides from Recce Pharmaceuticals's shareholder meeting presentation, Nov 22, 2016

  1. Slide 1: AGM Presentation

    Slide 1: AGM Presentation

    AGM Presentation 22 November 2016 Presented by Dr Graham Melrose (Executive Chairman) Recce Ltd© ASX: RCE 1

  2. Slide 2: Disclaimer

    Slide 2: Disclaimer

    Disclaimer ALL CURRENCY AMOUNTS ARE IN AUD UNLESS STATED OTHERWISE. DISCLAIMER This presentation has been prepared by Recce Ltd (the “Company”). It does not purport to contain all the information that a prospective investor may require in connection with any potential investment in the Company. You

  3. Slide 3: Corporate and investment summary

    Slide 3: Corporate and investment summary

    Corporate and investment summary Overuse of antibiotics has led to antibiotic resistant bacteria. Antibiotic resistant bacteria or superbugs have become a major world health issue. Recce is focused on developing a new class of synthetic anti-bacterials with a broad spectrum of activity against antib

  4. Slide 4: Recce synthetic antibiotics

    Slide 4: Recce synthetic antibiotics

    Recce synthetic antibiotics • Recce has synthesized and patented a new class of antibiotics. • These new compounds have demonstrated safety and efficacy in a range of pre-clinical tests to kill a number of common antibiotic resistant bacteria. • Recce’s new synthetic antibiotic compounds show positi

  5. Slide 5: Lead RECCE compound

    Slide 5: Lead RECCE compound

    Lead RECCE® 327 compound RECCE® 327 is our lead synthetic antibiotic candidate in pre-clinical development Extensive pre-clinical studies have demonstrated positive in-vitro (in the lab) and in-vivo (in animals) to date: • Demonstrates anti-infective properties against S. aureus and E. coli. • Impor

  6. Slide 6: RECCE antibiotics: Sepsis

    Slide 6: RECCE antibiotics: Sepsis

    RECCE® antibiotics Sepsis • “Sepsis affects over 26 million people worldwide each year - one third die” • “It is the largest killer of children and new-born infants in the world” • “Sepsis is increasing at an annual rate of 8-13%” • “In the United States, sepsis kills more people than colon cancer,

  7. Slide 7: Technology: Very resistant – P. aeruginosa (Gr-ve superbug)

    Slide 7: Technology: Very resistant – P. aeruginosa (Gr-ve superbug)

    Technology: Very resistant – P. aeruginosa (Gr-ve superbug) Pre-infection Full infection After 1 hour treatment with RECCE® 327 Complete kill 7

  8. Slide 8: RECCE kills at practical speeds

    Slide 8: RECCE kills at practical speeds

    RECCE® 327 kills at practical speeds* Rates of kill of standard bacteria S. aureus E. coli P. aeruginosa S. pyogenes C. difficile 20 – 60 20 – 60 1 – 24 20 – 60 20 – 60 minutes minutes hours minutes minutes Rates of kill of Superbugs S. aureus E. coli P. aeruginosa The same kill-rates for standard b

  9. Slide 9: RECCE does not Fail

    Slide 9: RECCE does not Fail

    RECCE® 327 does not Fail Number of repetitive uses before displaying loss of antibiotic activity S. aureus E. coli P. aeruginosa Commercial Commercial Commercial antibiotic antibiotic antibiotic 8 4 10 RECCE® Antibiotic >25 After repetitive use, the commercial antibiotic loses activity; RECCE® 327 D

  10. Slide 10: Technology – How it works

    Slide 10: Technology – How it works

    Technology – How it works RECCE® antibiotics attack protein in the cell wall of bacteria – outward pressure in the bacteria, causes only them to rupture. 10

  11. Slide 11: Technology – How it works

    Slide 11: Technology – How it works

    Technology — How it works Recce 3 RECCE® 327 Bacteria bursts @ 4 RECCE® 327 Redundant bacteria are absorbed @ RECCE® 327 @ BACTERIUM oe d : ‘ouTwaRD PRESSURE eve uu

  12. Slide 12: Natural vs Synthetic

    Slide 12: Natural vs Synthetic

    Natural vs Synthetic • Commercial antibiotics are naturally derived – superbugs to them have been forming for millenniums – and will continue to do so • RECCE® 327 is wholly synthetic – superbugs never formed in nature – designed for a purpose! 12

  13. Slide 13: Expected news flow next 12 months (calendar year)

    Slide 13: Expected news flow next 12 months (calendar year)

    Expected news flow next 12 months (calendar year) 2016 2017 Additional RECCE® 327 safety and efficacy data Final toxicology and efficacy test data Oral dosing toxicology and efficacy data in mice Rat pharmacokinetic results Anti-viral efficacy results in mice Dog pharmacokinetic results Anti-cancer

  14. Slide 14: Recce business model – strategy to create long-term value

    Slide 14: Recce business model – strategy to create long-term value

    Recce business model – strategy to create long-term value Pharma & biotech partnerships New class of Revenues, upfronts, synthetic milestones, royalties Recce synthetic antibiotics antibiotic platform Potential in multiple In-house disease indications Licensing of pipeline of drug distribution candi

  15. Slide 15: Board and management in place to deliver

    Slide 15: Board and management in place to deliver

    Board and management in place to deliver Dr Graham Melrose: Executive Chairman Peter Williams: CFO and Company Secretary Accomplished senior ASX finance professional with significant Founder and inventor. Former Chief Research Executive of local and international experience. Former VP Finance with J

  16. Slide 16: A supportive legislative and financial landscape globally for new antibiotics

    Slide 16: A supportive legislative and financial landscape globally for new antibiotics

    A supportive legislative and financial landscape globally for new antibiotics The global need for new antibiotics is urgent and a major economic and social issue. The rapid development of new antibiotics is supported by a range of initiatives by governments and private investors globally. Legislatio

  17. Slide 17: Supportive legislative and financial landscape

    Slide 17: Supportive legislative and financial landscape

    Supportive legislative and financial landscape Economics: • Former UK Prime Minister David Cameron commissioned a report analysing the economic and social costs of the problem and propose concrete actions to tackle it internationally. • The O’Neil Review on Antimicrobial Resistance published in 2015

  18. Slide 18: RECCE – a Technology

    Slide 18: RECCE – a Technology

    RECCE® 327 – a Technology Compared to the risk of a single opportunity from a one-use product - Recce’s technology enjoys the added security of multiple product opportunities. 18

Source: Internet Archive copy of recce.com.au

More decks from Recce Pharmaceuticals Ltd.

All 45 Recce Pharmaceuticals decks